RJA
HOOK

Raymond James & Associates’s HOOKIPA Pharma HOOK Stock Holding History

Raymond James & Associates’s Portfolio HOOK Stock Details HOOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,059
Closed -$142K – 4135
2021
Q1 		$142K Buy
+1,059
New +$128K ﹤0.01% 3709

Other funds holding HOOK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James & Associates's HOOK Position: Q2 2021 in Review

Raymond James & Associates sold out of HOOKIPA Pharma (HOOK) in Q2 2021, closing a stake of 1,059 shares — an estimated $142K sold.

Raymond James & Associates first reported a position in HOOK in Q1 2021 and held it in 1 quarter. The position peaked at $142K in Q1 2021. 71 funds tracked by Wall St. Rank hold HOOK as of Q2 2021.

  • Raymond James & Associates reported no remaining HOOKIPA Pharma position as of Q2 2021 after selling out during the quarter.
  • Raymond James & Associates sold 1,059 HOOKIPA Pharma shares in Q2 2021, an estimated $142K.
  • Raymond James & Associates first reported a position in HOOKIPA Pharma in Q1 2021 and held it in 1 quarter.
  • Raymond James & Associates's HOOKIPA Pharma position peaked at $142K in Q1 2021.
  • 71 funds tracked by Wall St. Rank held HOOKIPA Pharma as of Q2 2021.

Based on Raymond James & Associates's 13F filing for Q2 2021, filed 11 Aug 2021.